Remi Marty, PharmD

UCB
Brussels, Belgium

Market Access in International Markets for UCB Immunology portfolio.

Presentation(s):

• 1366: Cost Per Responder Analysis of Certolizumab Pegol Versus Adalimumab in Patients with Moderate to Severe Active Rheumatoid Arthritis and High Rheumatoid Factor Levels: A Payer Perspective from Canada and Brazil

  Monday, October 27, 2025
  10:30 AM - 12:30 PM Central Time

  Disclosure(s): UCB: Employee (Ongoing), shareholder (as part of employee incentive plan) (Ongoing)